Rising Pharmaceuticals debuts generic Canasa
Rising Pharmaceuticals is debuting its generic Canasa (mesalamine suppositories). The generic version of Allergan's branded drug is indicated to treat mild-to-moderately active ulcerative proctitis. It will be available in 1,000-mg strength.
“We’re pleased to add to our portfolio of generic medicines a valued treatment option for people living with mildly to moderately active ulcerative proctitis,” Ira Baeringer, Rising Pharmaceuticals chief operating officer said.
Mesalamine suppositories had a market value of roughly $263 million for the 12 months ended March 2019, according to IQVIA.
“We’re pleased to add to our portfolio of generic medicines a valued treatment option for people living with mildly to moderately active ulcerative proctitis,” Ira Baeringer, Rising Pharmaceuticals chief operating officer said.
Mesalamine suppositories had a market value of roughly $263 million for the 12 months ended March 2019, according to IQVIA.